Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q8N9N2

UPID:
ASCC1_HUMAN

ALTERNATIVE NAMES:
ASC-1 complex subunit p50; Trip4 complex subunit p50

ALTERNATIVE UPACC:
Q8N9N2; Q5SW06; Q5SW07; Q96EI8; Q9Y307

BACKGROUND:
The protein Activating signal cointegrator 1 complex subunit 1, also known as ASC-1 complex subunit p50, is integral to the cellular response to DNA damage through its involvement in the ASCC complex. It contributes to the activation of key transcription factors such as NF-kappa-B, SRF, and AP1 and is essential in gastrin-mediated SERPINB2 expression and neuromuscular junction development.

THERAPEUTIC SIGNIFICANCE:
Involvement of ASC-1 complex subunit p50 in diseases like Barrett esophagus and Spinal muscular atrophy with congenital bone fractures 2 highlights its potential as a target for therapeutic intervention. Exploring the functions of this protein could lead to innovative treatments for these conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.